NCT02499900

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 861 (actual)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Copaxone®	Subcutaneous Injections

Timeline

• Start date: 2015-08-10
• Primary completion: 2017-01-10
• Completion: 2017-06-02
• First posted: 2015-07-16
• Last updated: 2021-12-09
• Results posted: 2018-08-20

Locations

97 sites across 16 countries: United States, Argentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russia, Spain, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study